Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice
Antiviral Res. 2024 Mar 30:105877. doi: 10.1016/j.antiviral.2024.105877. Online ahead of print.ABSTRACTThe conventional inactivated split seasonal influenza vaccine offers low efficacy, particularly in the elderly and against antigenic variants. Here, to improve the efficacy of seasonal vaccination for the elderly population, we tested whether supplementing seasonal bivalent (H1N1 + H3N2) split (S) vaccine with M2 ectodomain repeat and multi-subtype consensus neuraminidase (NA) proteins (N1 NA + N2 NA + flu B NA) on a virus-like particle (NA-M2e) would induce enhanced cross-protection against different influenza viruses in...
Source: Antiviral Research - April 1, 2024 Category: Virology Authors: Jannatul Ruhan Raha Ki-Hye Kim Noopur Bhatnagar Rong Liu Chau Thuy Tien Le Bo Ryoung Park Phillip Grovenstein Surya Sekhar Pal Eun-Ju Ko Chong Hyun Shin Bao-Zhong Wang Sang-Moo Kang Source Type: research
Early application of IFN γ mediated the persistence of HBV in an HBV mouse model
Antiviral Res. 2024 Mar 29:105872. doi: 10.1016/j.antiviral.2024.105872. Online ahead of print.ABSTRACTThe antiviral activity of interferon gamma (IFNγ) against hepatitis B virus (HBV) was demonstrated both in vivo and in vitro in a previous study. IFNγ can suppress HBV replication by accelerating the decay of replication-competent nucleocapsids of HBV. However, in this study, we found that the direct application of the mouse IFNγ (mIFNγ) expression plasmid to the liver of an HBV hydrodynamic injection (HI) mouse model led to the persistence of HBV, as indicated by sustained HBsAg and HBeAg levels in the serum as well ...
Source: Antiviral Research - March 31, 2024 Category: Virology Authors: Jingjiao Song Xiliang Sun Yun Zhou Sheng Li Jun Wu Lu Yang Di Zhou Yan Yang Anding Liu Mengji Lu Roggendorf Michael Li Qin Dongliang Yang Source Type: research
Glucocorticoid receptor and specificity protein 1 (Sp1) or Sp3, but not the antibiotic Mithramycin A, stimulates human alphaherpesvirus 1 (HSV-1) replication
Antiviral Res. 2024 Mar 29:105870. doi: 10.1016/j.antiviral.2024.105870. Online ahead of print.ABSTRACTFollowing acute human alphaherpesvirus 1 (HSV-1) infection of oral-facial mucosal surfaces, sensory neurons in trigeminal ganglia (TG) are important sites for life-long latency. Neurons in the central nervous system, including brainstem, also harbor viral genomes during latency. Periodically, certain cellular stressors trigger reactivation from latency, which can lead to recurrent HSV-1 disease: herpes labialis, herpes stromal keratitis, and encephalitis for example. Activation of the glucocorticoid receptor (GR) by stres...
Source: Antiviral Research - March 31, 2024 Category: Virology Authors: Fouad S El-Mayet Vanessa Claire Santos Nishani Wijesekera Sydney Lubbers Kelly S Harrison Hafez Sadeghi Clinton Jones Source Type: research
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses
Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871. Online ahead of print.ABSTRACTThe spread of COVID-19 continues due to genetic variation in SARS-CoV-2. Highly mutated variants of SARS-CoV-2 have an increased transmissibility and immune evasion. Due to the emergence of various new variants of the virus, there is an urgent need to develop broadly effective specific drugs for therapeutic strategies for the prevention and treatment of COVID-19. Molnupiravir (EIDD-2801, MK-4482), is an orally bioavailable ribonucleoside analogue of β-D-N4-hydroxycytidine (NHC), has demonstrated efficacy against SARS-CoV...
Source: Antiviral Research - March 30, 2024 Category: Virology Authors: Andrei E Siniavin Vladimir A Gushchin Natal'ya S Shastina Elizaveta S Darnotuk Sergey I Luyksaar Leonid I Russu Anna M Inshakova Elena V Shidlovskaya Daria V Vasina Nadezhda A Kuznetsova Daria M Savina Ilya D Zorkov Inna V Dolzhikova Anna B Sheremet Denis Source Type: research
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors
Antiviral Res. 2024 Mar 28:105874. doi: 10.1016/j.antiviral.2024.105874. Online ahead of print.ABSTRACTThe main protease (MPro) of SARS-CoV-2, the causative agent of COVID-19, is a pivotal nonstructural protein critical for viral replication and pathogenesis. Its protease function relies on three active site pockets for substrate recognition and a catalytic cysteine for enzymatic activity. To develop potential SARS-CoV-2 antivirals, we successfully synthesized a diverse range of azapeptide inhibitors with various covalent warheads to target MPro's catalytic cysteine. Our characterization identified potent MPro inhibitors, ...
Source: Antiviral Research - March 30, 2024 Category: Virology Authors: Kaustav Khatua Yugendar R Alugubelli Kai S Yang Veerabhadra R Vulupala Lauren R Blankenship Demonta Coleman Sandeep Atla Sankar P Chaki Zhi Zachary Geng Xinyu R Ma Jing Xiao Peng-Hsun Chen Chia-Chuan D Cho Shivangi Sharma Erol C Vatansever Yuying Ma Ge Yu Source Type: research
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses
Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871. Online ahead of print.ABSTRACTThe spread of COVID-19 continues due to genetic variation in SARS-CoV-2. Highly mutated variants of SARS-CoV-2 have an increased transmissibility and immune evasion. Due to the emergence of various new variants of the virus, there is an urgent need to develop broadly effective specific drugs for therapeutic strategies for the prevention and treatment of COVID-19. Molnupiravir (EIDD-2801, MK-4482), is an orally bioavailable ribonucleoside analogue of β-D-N4-hydroxycytidine (NHC), has demonstrated efficacy against SARS-CoV...
Source: Antiviral Research - March 30, 2024 Category: Virology Authors: Andrei E Siniavin Vladimir A Gushchin Natal'ya S Shastina Elizaveta S Darnotuk Sergey I Luyksaar Leonid I Russu Anna M Inshakova Elena V Shidlovskaya Daria V Vasina Nadezhda A Kuznetsova Daria M Savina Ilya D Zorkov Inna V Dolzhikova Anna B Sheremet Denis Source Type: research
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors
Antiviral Res. 2024 Mar 28:105874. doi: 10.1016/j.antiviral.2024.105874. Online ahead of print.ABSTRACTThe main protease (MPro) of SARS-CoV-2, the causative agent of COVID-19, is a pivotal nonstructural protein critical for viral replication and pathogenesis. Its protease function relies on three active site pockets for substrate recognition and a catalytic cysteine for enzymatic activity. To develop potential SARS-CoV-2 antivirals, we successfully synthesized a diverse range of azapeptide inhibitors with various covalent warheads to target MPro's catalytic cysteine. Our characterization identified potent MPro inhibitors, ...
Source: Antiviral Research - March 30, 2024 Category: Virology Authors: Kaustav Khatua Yugendar R Alugubelli Kai S Yang Veerabhadra R Vulupala Lauren R Blankenship Demonta Coleman Sandeep Atla Sankar P Chaki Zhi Zachary Geng Xinyu R Ma Jing Xiao Peng-Hsun Chen Chia-Chuan D Cho Shivangi Sharma Erol C Vatansever Yuying Ma Ge Yu Source Type: research
DDX20 positively regulates the interferon pathway to inhibit viral infection
This study provides new evidence that DDX20 positively modulates the interferon pathway and restricts viral infection.PMID:38552910 | DOI:10.1016/j.antiviral.2024.105875 (Source: Antiviral Research)
Source: Antiviral Research - March 29, 2024 Category: Virology Authors: Zhiqiang Chen Jinyu Zhang Tingting Feng Xiujuan Wang Shimeng Zhou Wen Pan Zhengrong Chen Yongdong Yan Jianfeng Dai Source Type: research
Preclinical animal models to evaluate therapeutic antiviral antibodies
Antiviral Res. 2024 Mar 26:105843. doi: 10.1016/j.antiviral.2024.105843. Online ahead of print.ABSTRACTDespite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide effective virus-specific medical interventions. In order to develop these therapeutic antibodies, preclinical animal models are of utmost importance. Due to the variability in viral pathogenesis, immunity and overall character...
Source: Antiviral Research - March 28, 2024 Category: Virology Authors: Amse De Meyer Philip Meuleman Source Type: research
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals
Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869. Online ahead of print.ABSTRACTSARS-CoV-2 Omicron subvariants with increased transmissibility and immune evasion are spreading globally with alarming persistence. Whether the mutations and evolution of spike (S) Omicron subvariants alter the viral hijacking of human TMPRSS2 for viral entry remains to be elucidated. This is particularly important to investigate because of the large number and diversity of mutations of S Omicron subvariants reported since the emergence of BA.1. Here we report that human TMPRSS2 is a molecular determinant of viral entry f...
Source: Antiviral Research - March 28, 2024 Category: Virology Authors: Jimena P érez-Vargas Gabriel Lemieux Connor A H Thompson Antoine D ésilets Siobhan Ennis Guang Gao Danielle G Gordon Annika Lea Schulz Masahiro Niikura Ivan Robert Nabi Mel Krajden Pierre-Luc Boudreault Richard Leduc Fran çois Jean Source Type: research
Preclinical animal models to evaluate therapeutic antiviral antibodies
Antiviral Res. 2024 Mar 26:105843. doi: 10.1016/j.antiviral.2024.105843. Online ahead of print.ABSTRACTDespite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide effective virus-specific medical interventions. In order to develop these therapeutic antibodies, preclinical animal models are of utmost importance. Due to the variability in viral pathogenesis, immunity and overall character...
Source: Antiviral Research - March 28, 2024 Category: Virology Authors: Amse De Meyer Philip Meuleman Source Type: research
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals
Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869. Online ahead of print.ABSTRACTSARS-CoV-2 Omicron subvariants with increased transmissibility and immune evasion are spreading globally with alarming persistence. Whether the mutations and evolution of spike (S) Omicron subvariants alter the viral hijacking of human TMPRSS2 for viral entry remains to be elucidated. This is particularly important to investigate because of the large number and diversity of mutations of S Omicron subvariants reported since the emergence of BA.1. Here we report that human TMPRSS2 is a molecular determinant of viral entry f...
Source: Antiviral Research - March 28, 2024 Category: Virology Authors: Jimena P érez-Vargas Gabriel Lemieux Connor A H Thompson Antoine D ésilets Siobhan Ennis Guang Gao Danielle G Gordon Annika Lea Schulz Masahiro Niikura Ivan Robert Nabi Mel Krajden Pierre-Luc Boudreault Richard Leduc Fran çois Jean Source Type: research
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
Antiviral Res. 2024 Mar 21;225:105867. doi: 10.1016/j.antiviral.2024.105867. Online ahead of print.ABSTRACTMonoclonal antibody-based therapeutics have achieved remarkable success in treating a wide range of human diseases. However, conventional systemic delivery methods have limitations in insufficient target tissue permeability, high costs, repeated administrations, etc. Novel technologies have been developed to address these limitations and further enhance antibody therapy. Local antibody delivery via respiratory tract, gastrointestinal tract, eye and blood-brain barrier have shown promising results in increasing local c...
Source: Antiviral Research - March 23, 2024 Category: Virology Authors: Wenli Sun Yanling Wu Tianlei Ying Source Type: research
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
Antiviral Res. 2024 Mar 21;225:105867. doi: 10.1016/j.antiviral.2024.105867. Online ahead of print.ABSTRACTMonoclonal antibody-based therapeutics have achieved remarkable success in treating a wide range of human diseases. However, conventional systemic delivery methods have limitations in insufficient target tissue permeability, high costs, repeated administrations, etc. Novel technologies have been developed to address these limitations and further enhance antibody therapy. Local antibody delivery via respiratory tract, gastrointestinal tract, eye and blood-brain barrier have shown promising results in increasing local c...
Source: Antiviral Research - March 23, 2024 Category: Virology Authors: Wenli Sun Yanling Wu Tianlei Ying Source Type: research
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
Antiviral Res. 2024 Mar 21:105867. doi: 10.1016/j.antiviral.2024.105867. Online ahead of print.ABSTRACTMonoclonal antibody-based therapeutics have achieved remarkable success in treating a wide range of human diseases. However, conventional systemic delivery methods have limitations in insufficient target tissue permeability, high costs, repeated administrations, etc. Novel technologies have been developed to address these limitations and further enhance antibody therapy. Local antibody delivery via respiratory tract, gastrointestinal tract, eye and blood-brain barrier have shown promising results in increasing local conce...
Source: Antiviral Research - March 23, 2024 Category: Virology Authors: Wenli Sun Yanling Wu Tianlei Ying Source Type: research
